We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

MannKind Corporation (NASDAQ: MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind ( NASDAQ: MNKD) shares fell on Wednesday after the company reported second quarter revenue and adjusted profit below ...

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most si ...

Analysts anticipate MannKind to report an earnings per share (EPS) of $0.06. The announcement from MannKind is eagerly ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapies and delivery devices for serious endocrine and lung diseases. While we acknowledge the potential of MNKD as an investment, we ...